Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry

International Journal of Rheumatic Diseases

Volumn 17, Issue s3, 2014, Pages 1-8

  Mok, Chi Chiu ^a   Chan, Ka Yan ^b   Lee, Ka Lai ^c   Tam, Lai Shan ^d   Lee, Ka Wing ^e   Tat Chan, Eric Yuk ^f   Chan, Ka Ho ^f   Chan, Ka Man ^f   Helen Chan, Ka Yan ^f   Julia Chan, Pui Shan ^f   Chan, Yee Ki ^f   Lucia Chau, Shuk Yi ^f   Cheung, Tak Cheong ^f   Cheung, Tsang ^f   Chung, Ho Yin ^f   Ho, Carmen ^f   Kun, Emily ^f   Kwok, Lai Wa ^f   Kwok, Man Leung ^f   Kwok, Kitty ^f   Lam, Chi Kwai ^f   Lao, Weng Ng ^f   Lau, Chak Sing ^f   Lau, Yu Lung ^f   Yiu Lee, Anthony Kai ^f   Fai Lee, Tony Kwok ^f   Lee, Kwok Kei ^f   Jolly Lee, Man Yee ^f   Lee, Shui Shan ^f   Lee, Tsz Leung ^f   Yan, Tsz ^f   Lee, Samson ^f   Leung, Man Chi ^f   Li, Wai Ling ^f   Liu, Hor Ming ^f   Luk, Ming Chi ^f   Ma, Kai Yiu ^f   Mak, Lai Wo ^f   Mok, Mo Yin ^f   Daniel Ng, Kam Hung ^f   Ng, Woon Leung ^f   So, Ho ^f   Sung, Chi Keung ^f   Tan, Ronald F ^f   Sandy Tang, Shuk Kuen ^f   Wan, Man Choi ^f   Wong, Ching Han ^f   Wong, Kong Chiu ^f   Man, Shiu ^f   Wong, Pui Yan ^f   Wong, Jude ^f   Raymond Wong, Woon Sing ^f   Sandy Woo, Wai Shan ^f   Young, Kit Yu ^f   Yim, Cheuk Wan ^f   Carrel Yu, Ka Lung ^f   Catherine Yuen, Ka Yan ^f   Amy Yung, Ka Man ^f   more..

^a TUEN MUN HOSPITAL   (Hong Kong)

^b KOWLOON HOSPITAL   (Hong Kong)

^c PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^f NONE

Author keywords

Anti TNF ; Biologics; Real life; Registry; Rheumatic diseases

Indexed keywords

ABATACEPT; ADALIMUMAB; BELIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG RETENTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEPATITIS B; HERPES ZOSTER; HONG KONG; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; INJECTION SITE REACTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PSORIATIC ARTHRITIS; RASH; RECURRENT INFECTION; REGISTER; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEPTICEMIA; SEX DIFFERENCE; SKIN ALLERGY; SKIN INFECTION; SOFT TISSUE INFECTION; SPONDYLARTHRITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; AGE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; OPPORTUNISTIC INFECTION; PROPORTIONAL HAZARDS MODEL; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HONG KONG; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921292134     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12264     Document Type: Article

References (34)

1. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63, 1182-9.
2. Strand V, Khanna D (2010) The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 28 (3 Suppl 59), S32-40.
3. Kiltz U, van der Heijde D (2009) Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol 27 (4 Suppl 55), S108-11.
4. Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF (2013) Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis 72, 1675-9.
5. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ (2012) Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken) 64, 1649-56.
6. Palla I, Trieste L, Tani C et al. (2012) A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 30 (4 Suppl 73), S136-41.
7. Cortesi PA, Scalone L, D'Angiolella L et al. (2012) Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 30 (4 Suppl 73), S126-31.
8. van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508-19.
9. Braun J, Baraliakos X, Hermann KG et al. (2012) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 71, 878-84.
10. McInnes IB, Sieper J, Braun J et al. (2013) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. [Epub ahead of print].
11. Galloway JB, Hyrich KL, Mercer LK et al. (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50, 124-31.
12. Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J (2012) Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 64, 42-52.
13. Strangfeld A, Hierse F, Rau R et al. (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12, R5.
14. Glintborg B, Østergaard M, Krogh NS et al. (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72, 1149-55.
15. Mariette X, Gottenberg JE, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50, 222-9.
16. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L (2012) Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 71, 382-5.
17. Greenberg JD, Reed G, Decktor D et al. (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71, 1134-42.
18. Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 51(Suppl 6), vi37-43.
19. Hetland ML, Christensen IJ, Tarp U (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62, 22-32.
20. Strangfeld A, Hierse F, Kekow J, von Hinueber U et al. (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68, 1856-62.
21. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61, 560-8.
22. Sakai R, Tanaka M, Nanki T et al. (2012) Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 71, 1820-6.
23. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305, 1460-8.
24. Baert F, Noman M, Vermeire S et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348, 601-8.
25. van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9, 164-72.
26. van Dartel SA, Fransen J, Kievit W et al. (2013) Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72, 895-900.
27. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54, 2368-76.
28. Strangfeld A, Listing J, Herzer P et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301, 737-44.
29. Galloway JB, Mercer LK, Moseley A et al. (2013) Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 72, 229-34.
30. García-Doval I, Pérez-Zafrilla B, Descalzo MA et al. (2010) Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 69, 1751-5.
31. Sakai R, Komano Y, Tanaka M et al. (2012) Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 1125-34.
32. To KW, Reino JJ, Yoo DH, Tam LS (2013) Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. Respirology 18, 765-73.
33. Emery P, Breedveld FC, Hall S et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-82.
34. Krieckaert CL, Nurmohamed MT, Wolbink GJ (2012) Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 71, 1914-5.